CYP2B6药物遗传变异影响人乳腺癌细胞类固醇激素代谢
本研究在T47D乳腺癌细胞中稳定过表达CYP2B6野生型及*4、*5、*6、*9变异体,用HPLC-MS/MS分析睾酮和雌二醇代谢产物。发现CYP2B6*6过表达增加16α-羟基睾酮生成,而*4和*9代谢降低,*5降低16β-羟基睾酮水平,提示变异可改变激素平衡。
要点
- CYP2B6常见变异*4、*5、*6、*9可改变睾酮代谢产物谱。
- CYP2B6*6过表达增加16α-羟基睾酮,*4和*9降低代谢。
- 变异导致的激素代谢改变可能促进肿瘤微环境。
核心结论
- 常见CYP2B6变异改变人乳腺癌模型中睾酮代谢,可能破坏类固醇激素平衡并促进肿瘤环境。
- 研究提示药物遗传学分析在乳腺癌风险评估中可能具有意义。
研究设计与样本
- 研究用逆转录病毒pMOWS载体系统在T47D乳腺癌细胞中稳定过表达CYP2B6野生型及变异体*4、*5、*6、*9。
- 用HPLC-MS/MS分析睾酮或雌二醇与CYP2B6、CYP1B1 supersomes及修饰T47D细胞孵育后的代谢产物。
- 同时测试芳香化酶将睾酮代谢物转化为雌激素的过程。
主要发现
- CYP2B6 supersomes主要形成16β-羟基睾酮和2-羟基雌二醇,而CYP1B1主要产生16α-羟基睾酮和4-羟基雌二醇。
- T47D中CYP2B6*6过表达增加16α-羟基睾酮形成,而*4和*9较野生型代谢降低。
- CYP2B6*5产生降低的16β-羟基睾酮水平。
- 芳香化酶将16α-代谢物转化为雌三醇,将16β-羟基睾酮转化为16-表雌三醇。
临床怎么用
- 临床药师可关注CYP2B6变异状态对乳腺癌患者类固醇激素代谢的潜在影响。
- 在乳腺癌风险评估中,可考虑药物遗传学分析的价值,但需进一步临床验证。
局限性
- 研究仅在人乳腺癌细胞模型中进行,尚未在人体内证实。
- 未报告样本量、P值等统计细节,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: CYP2B6 is a key enzyme involved in the metabolism of steroid hormones such as testosterone and estradiol. Common genetic CYP2B6 variants (*4, *5, *6, *9) are associated with reduced enzymatic activity and have been linked to increased breast cancer risk and poor prognosis. However, the impact of these genetic variants on testosterone and estradiol metabolism in humans is not understood. Therefore, this study aimed to investigate how these pharmacogenetic CYP2B6 variants affect metabolism of these steroid hormones in a human breast cancer model and how this may contribute to altered steroid hormone profiles in breast cancer. METHODS: T47D breast cancer cells were engineered to stably overexpress CYP2B6 wild type and the variants *4, *5, *6 and *9 using a retroviral pMOWS vector system. The metabolites 16α-/16β-hydroxytestosterone and 2-/4-hydroxyestradiol were analysed using HPLC-MS/MS after incubation of testosterone or estradiol with CYP2B6 and CYP1B1 supersomes and the modified T47D cells. Conversion of testosterone metabolites to oestrogens by aromatase was also tested. RESULTS: CYP2B6 supersomes predominantly formed 16β-hydroxytestosterone and 2-hydroxyestradiol, while CYP1B1 predominantly produced 16α-hydroxytestosterone and 4-hydroxyestradiol. CYP2B6*6 overexpression in T47D increased 16α-hydroxytestosterone formation, while *4 and 9 showed decreased metabolism compared to wild type. CYP2B6*5 produced reduced 16β-hydroxytestosterone levels. Aromatase converts 16α-metabolite to estriol and 16β-hydroxytestosterone to 16-epiestriol. CONCLUSIONS: This study demonstrates that common CYP2B6 variants alter testosterone metabolism in a human breast cancer model, potentially disrupting steroid hormone balance and contributing to a tumour-promoting environment. These findings highlight the potential relevance of pharmacogenetic profiling in breast cancer risk assessment.
引用
- Hoffmann M, Müller JP, Düsterhöft S, et al. Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells. Br J Clin Pharmacol. 2026. PMID: 41636472. doi:10.1002/bcp.70473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。